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Abstract: Here we present the case of a 60-year-old woman with a rare sellar region atypical teratoid/rhabdoid tumor (AT/RT), compli-
cated by lung metastasis and treated with neurosurgery, radiotherapy, and chemotherapy. The patient had recurrent headache associated 
with left cavernous sinus syndrome after a previous endonasal transsphenoidal resection for a presumptive pituitary macroadenoma. 
Pituitary magnetic resonance imaging showed a tumor regrowth in the original location with a haemorrhagic component involving the 
left cavernous sinus. A near complete transsphenoidal resection of the sellar mass was performed followed by 3 months of stereotactic 
radiotherapy. Because of a worsening of the general clinical conditions, respiratory failure, and asthenia, the patient underwent a con-
trast enhanced computer tomography of the whole body which showed the presence of lung metastasis. The histopathological diagnosis 
on samples from pituitary and lung tissues was AT/RT. The patient survived 30 months after diagnosis regardless chemotherapy. In the 
adult, the AT/RT should be considered as a possible rare, aggressive, and malignant neoplasm localized in the sella turcica.
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Introduction
Atypical teratoid/rhabdoid tumor (AT/RT) occurs 
mainly in in children younger than 3 years of age. 
This tumor is similar in appearance to a rhabdomyo-
sarcoma but the cells differ from the expected mor-
phological and immunohistochemical features of 
muscle. A tumor composed of rhabdoid cells in the 
central nervous system (CNS), was first reported in 
1985. The name atypical teratoid/rhabdoid tumor 
(AT/RT) exemplifies the tumors disparate mixtures 
of rhabdoid, primitive neuroepithelial, mesenchymal, 
and epithelial components, although the tumors may 
be composed entirely or partly of rhabdoid cells.1–4 
The histologic and immunohistochemical features of 
this neoplasm have been extensively described.5–10 
The polymorphous histology prompts misdiagno-
sis of AT/RT as primitive neuroectodermal tumor 
(PNET), medulloblastoma, glioblastoma, choroid 
plexus carcinoma, or malignant teratoma5,6,11–13 The 
development of AT/RTs have been associated with a 
specific genetic alteration, that is, mutations of the 
INI1/hSNF5 gene located on chromosome 22q11.2.14 
The INI1/hSNF5 gene encodes a component of the 
SWI/SNF chromatin remodelling complex, interact-
ing with sequence specific DNA binding proteins 
such as c-Myc and EBNA-2.15 This genetic hallmark 
of AT/RT, either mutation or deletion of both copies 
of the INI1/hSNF5 gene, is seen in approximately 
70% of tumors. A smaller number have reduced 
expression at the RNA or protein level, indicative 
of a loss-of-function event. Loss of INI1 protein 
expression in the tumor cells is seen in all cases of 
AT/RT. Demonstrating this by immunohistochemis-
try has been suggested as a useful marker to distin-
guish AT/RTs from other malignant CNS tumors.16 
Loss of expression of INI1 as detected by immuno-
histochemical staining correlates with deletion and 
mutations of the INI1 gene.17
Multiple therapeutic approaches have been 
attempted over the last 2 decades in an attempt to 
increase survival in these patients without much 
 success.18 Radiation therapy seems to be the most 
important component of therapy. There is no accepted 
standard chemotherapy, but intensive high-dose che-
motherapy may be more effective. Efforts to delay 
radiation often fail, and most reported cases of sur-
vivors, even when including high-dose chemother-
apy, frequently require repeat surgery and radiation. 
 Overall, patients usually succumb to their disease 
between 6 months and 1 year from diagnosis.
clinical case
We describe the clinical history of an obese 60-year-
old woman, married with 3 children, who previously 
underwent an endonasal transsphenoidal resection for 
an intrasellar nonfunctioning presumptive pituitary 
macroadenoma invading the left cavernous sinus. At 
the first clinical observation, the patient presented 
with frontotemporal stabbing pain, insomnia, left 
diplopia, and convergent strabismus. After neurosur-
gery, the pathology study showed that the mass could 
be classified as atypical pituitary adenoma ACTH-, 
GH-, PRL-, TSH-, FSH-, chromogranin A-, with 
light cytoplasmatic positivity for pan-cytokeratin, 
LCA-, Vimentin+, S100-, EMA-, CD34-, CD1a-, 
p53+(10%), ki67+(30%).
One month after resection, the patient was read-
mitted to our clinic for headache associated with pain 
unresponsive to indomethacin. The patient showed 
left eye lachrymation, photophobia, nausea, diplopia, 
and signs of paresis of the IV pair of cranial nerve. She 
underwent magnetic resonance imaging (MRI) of the 
sella turcica with 1.5T superconductive units before 
and after an intravenous injection of contrast medium 
(0.1 mmol/kg of body weight). MRI showed the tumor 
regrowth in the original sellar location with a haemor-
rhagic component involving the left cavernous sinus 
and encasing the internal carotid artery (Fig. 1). A new 
transsphenoidal resection was performed with a near 
complete resection of the sellar mass. The pathology 
Figure 1. Coronal Ce Se T1W (A) and TSe T2W (B) MRI showing 
 pituitary mass with dishomogeneous enhancement and low signal T2W 
with extrasellar and lateral extension involving the left cavernous sinus 
and encasing the internal carotid artery.
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examination identified a neoplastic fibrous stroma tis-
sue infiltrated by a population of pleomorphic cells 
with abundant eosinophilic cytoplasm and hyperchro-
matic nuclei concluding as presumptive atypical pitu-
itary adenoma. After 2 months, she again presented 
headache, abnormal right-directional gazing, diplopia 
in all directions of gaze, and exophthalmos. The MRI 
showed a large and dishomogeneus sellar mass with 
lateral, inferior, and anterior extension involving the 
cavernous sinus, the sphenoidal bone with sinus inva-
sion, the left orbital apex with orbital fissures, and the 
optic canal (Fig. 2). The patient underwent 3 months 
of stereotactic radiotherapy (17 Gy to the periphery 
and 34 Gy to the center of the residual tumor). A few 
months later, because of a worsening of the general 
clinical situation, dyspnea, and asthenia, a contrast 
enhanced computed tomography (CECT) scan of the 
whole body revealed several metastases involving the 
pulmonary parenchyma bilaterally (Fig. 3). The patient 
underwent a thoracoscopic atypical lung  resection. 
All the surgical specimens including the sellar and 
lung tissue neoplasm were reviewed by a referent 
neuropathological centre. The final diagnosis was 
secondary lung localization of AT/RT with primary 
pituitary localization. Therefore, systemic antineo-
plastic therapy was started with doxorubicin (DOXO) 
and vinorelbine (VNL) (DOXO 37.5 mg/mq gg 1–2; 
VNL 30 mg/mq gg 1–8). After 9 cycles, the total body 
CECT control demonstrated a mild progression of 
the sellar mass and stability of the lung metastasis. 
 Stereotactic radiotherapy (SRT) was then performed 
on the residual sellar mass. As a complication of SRT, 
Figure 2. Coronal (A) and axial (B) Ce Se T1W MRI showing a large and 
heterogeneous sellar mass with lateral and anterior extension involving 
left orbital apex, orbital fissures, and optic canal. The arrow indicates the 
encasing of the optical nerve.
Figure 3. pulmonary CeCT showing several nodular metastases in axial 
slices of both lungs.
the patient showed cerebrospinal fluid fistulas treated 
surgically. After treatment, the patient underwent an 
additional CECT, which showed a progression of the 
disease. A CT of the head revealed a huge invasive 
sellar and extra sellar mass that eroded the sphenoid 
bone, with invasion of the ethmoid and erosion of 
the anterior cranial fossa. A large component of the 
mass occupied the nasopharinx (Fig. 4); a progression 
of the lung localization was also observed. A therapy 
consisting in carboplatin AUC 5/taxolo 175 mg/mq 
Figure 4. CeCT of the head showing a huge invasive sellar and nasophar-
inx mass that eroded the sphenoid bone, including clivus, sellar floor, and 
ethmoid with erosion of the anterior cranial fossa.
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every 21 days was started. During the second cycle, 
the clinical condition of the patient deteriorated. She 
presented with hyposthenia and paraesthesia of the 
upper and lower limbs, hearing impairment, reduc-
tion of visual acuity, nose bleeding, and dyspnea. 
 Unfortunately, 30 months after the first neurosurgical 
treatment, she died.
Laboratory studies
The biochemical evaluation before neurosurgery 
revealed a normal adenohypophyseal function. After 
the second neurosurgery resection, a condition of global 
adeno-neuro-hypophyseal hypofunction (ACTH , 1 
pg/mL [reference range 5–60 pg/mL], FT3 0.97 pg/
mL [reference range 1.8–4.6 pg/mL], FT4 0.78 ng/dL 
[reference range 0.93–1.71 ng/dL], FSH 1.4 mUI/mL 
[reference range 1.5–12.4 mUI/mL], LH 0.1 mUI/mL 
[reference range 1.7–8.6 mUI/mL], cortisol 0.2 µg/dL 
[reference range 7–25 µg/dL], urinary free corti-
sol , 20 µg/dL [reference range 30–130 µg/dL])19 
was found and a replacement therapy was established. 
Molecular studies performed on tissue obtained 
by lung biopsies demonstrated a deletion of chro-
mosome 22q (probe Vysis LSI 22q11.2/Tel Vysion 
22q13:ratio 22q11/22q13 = 0.69).20
pathological Findings
The primitive diagnosis of the sellar lesion after the 
first neurosurgery was nonfunctioning presumptive 
atypical pituitary adenoma, with immune-histochemi-
cal negativity for GH, PRL, LH, FSH, TSH, and ACTH 
(data not shown). The recurrent sellar lesion (Fig. 5A 
and B) and multiple lung metastases (Fig. 5C–E) were 
then reviewed at our institution and showed a neoplasm 
composed of small- to medium-sized polygonal cells 
arranged in cords or ribboned pattern with oval nuclei, 
vesicular chromatin, and eosinophilic cytoplasm. In 
some fields, large cells with frank rhabdoid appearance 
were evident and showed eccentrically placed vescicu-
lar nuclei containing prominent nucleoli, with paranu-
clear inclusion and eosinophilic cytoplasm. These cells 
grew singly in a fibrous stroma or in clusters. There were 
atypical mitosis and apoptotic figures. The prolifera-
tion labelling index, measured by MIB-1 monoclonal 
antibody to the Ki67, was 25%. Immunohistochemi-
cal evaluation showed focal positivity for epithelial 
membrane antigen, cytokeratin, smooth muscular 
actin, and gliofibrillary acidic protein. These multid-
ifferentiation features in accord with the histological 
findings suggested the possibility of an AT/RT, which 
was validated by the lack of immunostaining for INI1 
protein in neoplastic cells compared with positivity of 
the internal control represented by the endothelial cells 
(Fig. 5B and E). The final histological diagnosis was 
a World Health Organization (WHO) grade IV AT/RT 
with primary location in the sella turcica and second-
ary location in the lung. Written consent was obtained 
from the husband of the patient to reproduce informa-
tion and photographs appearing in this work.
Discussion
Here we describe the case of a middle-aged obese 
woman presenting with a sella turcica AT/RT with 
suprasellar extension. AT/RT is a rare,  aggressive, 
Figure 5. Hematoxylin and eosin staining (A, c and D) and immunohistochemical analysis (B and e) of the recurrent sellar lesion (A and B) and of the 
lung metastases (c–e). (A) The recurrent sellar neoplasm is composed of medium-sized, round cells with distinct borders, eccentric nuclei and prominent 
nucleoli. (B) The immunohistochemical analysis for INI1 protein shows a loss of positive immunostaining with the exception of positive staining in the 
endothelial cells (arrow). The lung metastasis of sellar AT/RT (c and D) shows plump and round cells with vescicular nuclei, evident nucleoli and clear 
cytoplasm; the neoplastic cells are negative for INI1 protein while the endothelial cells show positive immunostaining (arrow) (e). Scale bar = 50 µm.
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and malignant disease typical of infancy and child-
hood affecting the central nervous system, first 
defined as “atypical teratoid tumor.”21 Based on his-
tological evidence of diffuse proliferation of atypical 
large cells with eccentrically located nuclei, promi-
nent nucleoli, and abundant cytoplasm (rhabdoid 
cells), the disease was later referred to as AT/RT of 
the brain in order to emphasize the variable com-
bination of rhabdoid cells, epithelial cells, and 
primitive neuroectodermal, as well as mesenchymal 
features,1 Its occurrence in adult patients is extremely 
rare, as 95% of reported patients are 5 years old or 
younger.8,22 Only 32 documented cases have been 
described in adults to date, usually located in the 
cerebral hemisphere, cerebellum, and spinal cord, 
even if unusual locations such as the mediastinum, 
liver, neck, shoulder, and retroperitoneum have 
been described.4,23 A unique presentation of a rare 
case of adolescent AT/RT confined to the leptom-
eninges with no obvious intraparenchymal primary 
lesion and no focal neurological deficit has been also 
reported.24 Occurrence of AT/RT in the sellar region 
is rare, with only 7 cases reported so far.25,26 The 
rare incidence of this lesion, in particular in adults, 
may lead to its misdiagnosis as in the case reported 
here where the early diagnosis was pituitary mac-
roadenoma with suprasellar extension. However, 
our patient’s age and the sellar origin of her tumor 
may argue against a diagnosis of AT/RT and dictate 
a differential diagnosis with pituitary carcinoma or 
metastasis. The definitive diagnosis might be carried 
out through loss of immunohistochemical INI1 pro-
tein expression due to mutations of the INI1/hSNF5 
gene.27,28 The prognosis of AT/RT is poor both in 
adults and in the pediatric population, although long-
term survival is possible in adult AT/RT cases after 
a combined approach including surgery, adjuvant 
radiotherapy, and chemotherapy.25,29 Postoperative 
radiotherapy is crucial in the treatment of AT/RT,30,31 
and our patient underwent this treatment to have the 
remaining tissue removed closer to the sinus cavern-
ous not excised by the neurosurgeon. This combined 
approach, performed before the final pathological 
diagnosis, allowed us to observe a better prognosis 
in the patient with a survival of 30 months. In con-
clusion, AT/RT should be considered in the differen-
tial diagnosis of aggressive tumors with sella turcica 
localization even in middle-age individuals.
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